U.S. to Consider Expanding Medicare Drug Price Negotiation


The Trump administration is considering expanding Medicare’s ability to negotiate the cost of drugs by giving private payers a role in setting the price of medicines administered in hospitals and doctors’ offices, Health and Human Services Secretary Alex Azar said on Monday, according to a report in US News and World Report.

Azar’s comments provided more details on the plan to lower prescription drug costs for Americans announced on Friday by President Donald Trump.

While Trump assailed “middlemen,” an apparent reference to health insurers and pharmacy benefit managers (PBMs), for pocketing negotiated rebates on drugs rather than passing savings to consumers, the proposal discussed on Monday appears to see them as part of the solution to high prices.

Read the full article.

Related Content